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CAREGIVING STRAIN FOLLOWING AUTOLOGOUS BMT 
Eldredge, D.; Nail, L.; Mazim~, R. Oregotz Healt,~ & ScieJzce U17ive~'- 
sity, Portlalzd, OR. 
Background / Purpose: Responsibility for caring for high-risk 
medically-fragile patients following autologous BMT is vested in 
care partners (CPs) who have agreed to provide complex care at 
home. Although CPs are instructed in home care activities, no 
studies have analyzed what patient support is actually provided by 
CPs at home. The purpose of this study was to describe the effect 
of CPs preparation for home care, mutuality, and patient func- 
tion on caregiver strain. Theoretical Model: Family caregiving 
was viewed from an interactionist perspective suggesting that 
characteristics and interactions among CPs, patients, and the 
health care system influence the nature of caregiving situation 
and subsequent outcomes. Methods: Descriptive longitudinal 
study, collected via self-report questionnaire. Data analysis: Mul- 
tiple regression techniques were used to examine relationships 
among variables. These pre l iminary analyses are based on 
responses of 33 CPs of autologous BMT patients (average age 49 
years, 72% female, 84% Caucasian, 80% married) who rated 
mutuality and caregiving preparation at hospital discharge and 
strain from caregiving activities, and patient fnnction 2 weeks 
later. Results: At discharge, CPs felt well-prepared to meet care- 
giving challenges (mean 3.1, range 0-4). At 2 weeks post dis- 
charge, CPs reported patients have modest disruption in physical 
and psychological fimctioning (mean SIP = 14.49% and 13.21% 
respectively). CPs reported the most strain when providing emo- 
tional support (mean 2.27), naaking decisions (mean 2.01), and 
supervising nutritional intake (mean 1.92; range 1-4). The major 
predictor of both emotional  and total caregiving strain was 
patient psychological function (R2 =.49; p=.001); contrary to 
findings in other studies, disruption in physical function did not 
predict caregiving strain, hnplications: CPs feel prepared to meet 
patients' needs; however, these data suggest CPs need guidance 
in providing emotional support to BMT patients. Skilled trans- 
plant nurses are in an ideal position to teach these skills. Funding: 
ONS Foundation 
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ORAL (PO) VALGANCICLOV|R (VGC) FOR PREEMPTIVE THERAPY OF 
CYTOMEGALOVIRUS (CMV) ANTIGENEMIA (AG) IN HEMATOPOIETIC 
STEM CELL TRANSPLANT (HSCT) RECIPIENTS 
Leather, H.L.7; Meyer, C.L.2; T'T~ijzgard, J.R. ~" 1. Phal'mac3, , St, a~cls 
Hospital at the UMversity of Flol"ida, Gai71esville, FL; 2. &~iversity of 
Florida College of Medici71e, GaiTzesvi/h,, FL. 
One of the most problematic pathogens following HSCT is 
CMV, and if disease occurs, is associated with significant mor- 
bidity and mortality. The standard treatment for CMV AG is 
ganciclovir (GCV) or foscarnet. Because of shortages of intra- 
venous ganciclovir, we used an alternative, VGC, in our outpa- 
tient CMV antigenemia positive patients (pts). VGC, is a pro- 
drug of GCV that is rapidly converted into GCV following PO 
administrat ion.  METHODS:  We prospect ively treated all 
HSCT pts with CMV AG in our outpatient clinic from 8/01 to 
10/02 using VGC 900mg PO BID x 14 days, then 900rag PO 
QD x 7 days. RESULTS: 19 patients [mean age 49 years] were 
treated for 22 episodes of CMVAg [7 MUD,  8 ALLO, 2 UCB, 
1 NST  MUD,  1 AUTO].  One patient had simultaneous CMV 
enterocolitis, at the start of therapy. The median time from 
CMV AG +ve to -ve from the start of treatment was 9 days. Of 
the 22 episodes, 2 did not complete the 2 i -day course as pre- 
scribed, one because of increased hepatic transaminases, and an 
administrative error in the second. Median duration of therapy 
was 21 days [range 14 - 21]. Acute GVHD (> Grade 2)was pres- 
ent in 8 episodes of +ve CMV AG. All the pat ients with 
aGVHD had nausea, but all had negative gut biopsies. The  
mean WBC at the start of VGC treatment was 6.22 x 109/L 
[range 0.9 - 20 x 109/L], and declined to 3.88 x 10°/L [0.9 - 
11.6 x 10~)/L] at the end of the treatment. No patient had an 
ANC < 500/mm 3during treatment, or for one week after thera- 
py. Platclet counts, hemoglobin and serum creatinine remained 
stable over the t reatment  course. Nausea was reported in 7 
episodes of treatment. Concomitant vomiting, not necessitating 
t reatment  discont inuat ion occurred in 2 t reatment  courses. 
CONCLUSION:  VGC is well tolerated and appears to be as 
effective as GCV in HSCT recipients without GI GVHD.  We 
plan to compare the response rates, time to response, and toler- 
ability with VGC in this cohort of patients to a matched cohort 
receiving GCV. 
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OLANZAPINE FOR PERSISTENT NAUSEA AND ANOREXIA AFTER 
HEMATOPOIETIC STEM CELL TRANSPLANTATION 
Bur~y~ski, J.A/; H@%ann, R.J.2; T~7olf, R.C/ 1. Pharmacy, Mayo 
CliMe, Rochester, MN; 2.3/iayo Clildc-Hematology, Rochester, ]kiN. 
Persistent nausea and anorexia frequently occur following high- 
dose chemoradiotherapy and hematopoietic stem cell transplanta- 
tion (HSCT). This may adversely impact patients overall well-being 
and result in dehydration, mahmtrition, or electrolyte disorders. The 
prevalence of anore~a following HSCT has previously been shown 
to be high (66% at Day +50). The standard approach to the manage- 
ment of these symptoms remains empiric. Olanzapine, an atypical 
antipsychotic agent with complex physiologic effects on several neu- 
rotransmitters, has been associated with appetite stimulation and 
weight gain in various populations. Recent reports and anecdotal 
experience suggest benefit for patients with nausea related to cancer 
chemotherapy or advanced cancer. Following institutional IRB- 
approval, we retrospectively reviewed the Mayo Clinic experience. 
From 8/2000 through 9/2002 a total of 49 adult patients (35 
female/14 male; age 20-76 years) received olanzapine for nausea or 
anore~a following HSCT (44 autologous/5 allogeneic). Underlying 
diagnoses included lymphoma (n=22), myeloma (n=lS), amyloidosis 
(n=8) and leukemia (n=4). Condit ioning regimens utilized were 
BEAM (n=21), LPAM 140 or 200 (n=22), CyTBI (n=3), TBIfVPI6 
(n=2) and cladribine/thiotepa (n=l). Open-label olanzapine 2.5 mg 
to 10 nag/day in single or divided doses was administered for symp- 
toms persisting despite alternative antiemetics. Olanzapine was start- 
ed between Day +4 and Day +75 (median = Day +18) after HSCT. 
At the time of olanzapine initiation, patients were ceiving zero to 
five additional anfiemetics or appetite stimulants (median = 3). Dura- 
tion of olanzapine therapy ranged from i to 65 days (median = 10 
days). Subjective assessment of improvement in nausea or anorexia 
was defined as probable/possible (59.2%), unlikely/unable to assess 
(24.5%), or no impact (16.3%). Changes in oral caloric intake and 
body weight before and after olanzapine are presented in the table. 
Although oral intake improved, a net weight loss was observed. 
Olanzapine was generally well tolerated, although isolated cases of 
neutropenia, elevated LFFs and hypercholesterolemia appeared to 
be associated. Our initial experience is intriguing and a prospective, 
controlled trial is indicated. We believe this is the first report on the 
use of olanzapine for nausea or anorexia following HSCT. 
Pre-olanzapine caloric intake (kcal/day) 
Post-olanzapine caloric intake (kcal/day) 
Median Mean Range 
361 499 0-1700 
1130 1055 0-2120 
Weight change (kg) [net weight loss] -0.6 -0.65 - 10 to +7.7 
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BONE MARROW ASPIRATES AS PART OF ROUTINE DONOR ASSESS- 
MENT FOR ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION 
CAN REVEAL OCCULT HEMATOLOGICAL MALIGNANCIES IN ASYMP- 
TOMATIC INDIVIDUALS 
Kiss, ~F.L.1; Daly, A.I; Mes9lTer, H.A.I; Jamal, 2~ 1; Gala/, 4. ~; Spa~zev, 
D.:; Rubilz, S/; Cha*@ H/; Lipto77, J .H/ 1. Department of Medical 
OJTcology aTz,t Hematology, Princess l~Iargaret Hospital, Toronto, ON, 
Cmzacla; 2. S,nnybT"ook and WomelTs College Healt,b &ie*zces CeT~ter, 
To~wTto, ON, Cmzada; 3. The 3/io~lctol7 HospitAl, Mollctml, NB, Gl,zada. 
Assessment of normal donors prior to allogeneic stem cell 
transplantation i cludes a medical history, physical examination 
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